Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease

Anna Alisi, Sara Ceccarelli, Nadia Panera, Federica Prono, Stefania Petrini, Cristiano De Stefanis, Marco Pezzullo, Alberto Tozzi, Alberto Villani, Giorgio Bedogni, Valerio Nobili, Anna Alisi, Sara Ceccarelli, Nadia Panera, Federica Prono, Stefania Petrini, Cristiano De Stefanis, Marco Pezzullo, Alberto Tozzi, Alberto Villani, Giorgio Bedogni, Valerio Nobili

Abstract

Atypical fibroblast growth factors (FGF) 21 and 19 play a central role in energy metabolism through the mediation of Klotho coreceptor. Contradictory findings are available about the association of FGF21 and FGF19 with nonalcoholic fatty liver disease (NAFLD) in humans. We investigated the association of serum FGF21, FGF19 and liver Klotho coreceptor with non-alcoholic steatohepatitis (NASH) and fibrosis in children with NAFLD. Serum FGF21 and FGF19 were measured in 84 children with biopsy-proven NAFLD and 23 controls (CTRL). The hepatic expression of Klotho coreceptor was measured in 7 CTRL, 9 patients with NASH (NASH+) and 11 patients without NASH (NASH-). FGF21 and FGF19 showed a tendency to decrease from CTRL (median FGF21 = 196 pg/mL; median FGF19 = 201 pg/mL) to NASH- (FGF21 = 89 pg/mL; FGF19 = 81 pg/mL) to NASH+ patients (FGF21 = 54 pg/mL; FGF19 = 41 pg/mL) (p<0.001 for all comparisons) and were inversely associated with the probability of NASH and fibrosis in children with NAFLD. The hepatic expression of Klotho coreceptor was inversely associated with NASH (R(2) = 0.87, p<0.0001) and directly associated with serum FGF21 (R(2) = 0.57, p<0.0001) and FGF19 (R(2) = 0.67, p<0.0001). In conclusion, serum FGF19 and FGF21 and hepatic Klotho expression are inversely associated with hepatic damage in children with NAFLD and these findings may have important implications for understanding the mechanisms of NAFLD progression.

Conflict of interest statement

Competing Interests: Dr. Anna Alisi is a PLOS ONE Editorial Board member, but this does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1. NASH and serum levels of…
Figure 1. NASH and serum levels of FGF21 and FGF19.
Distribution of serum FGF21 (panel A) and FGF19 (panel B) in controls, NAFLD children without NASH (NASH−) and NASH children with NASH (NASH+). Lines superimposed to dot-plots are medians.
Figure 2. Probability of NASH and fibrosis…
Figure 2. Probability of NASH and fibrosis as a function of serum FGF21 and FGF19.
Probability of NASH and fibrosis of any degree as a function of loge-transformed values of FGF21 and FGF19 (see text for further details on statistical analysis). Abbreviations: NASH = non-alcoholic steatohepatitis; loge = natural logarithm; AIC = Akaike information criterion. Circles are means and bars 95% confidence intervals.
Figure 3. Association between the hepatic expression…
Figure 3. Association between the hepatic expression of Klotho, liver histopathology and serum FGF21 and FGF19.
Association of Klotho with histopathology, FGF21 and FGF19 (see text for further details on statistical analysis). Abbreviations: loge = natural logarithm; RMSE = root mean squared error of the estimate; R2 = coefficient of determination; AIC = Akaike information criterion. Circles are means and bars 95% confidence intervals.
Figure 4. Representative confocal immunofluorescence for expression…
Figure 4. Representative confocal immunofluorescence for expression and intracellular distribution of Klotho co-receptor.
The representative confocal immunofluorescence was performed on liver tissue cryostat sections OCT-embedded. The staining of Klotho co-receptor in the overweight-obese children without NAFLD (A), in the NAFLD overweight-obese children without NASH (B), and in the overweight-obese children with NASH (C) is shown in green. The nuclei are revealed by specific DAPI staining, displayed in blue. The white bar represents a 30 µm length.
Figure 5. Representative confocal immunofluorescence of Klotho…
Figure 5. Representative confocal immunofluorescence of Klotho co-receptor localization in liver tissues.
The representative confocal immunofluorescence was performed on liver tissue cryostat sections OCT-embedded. (A–C) Co-staining of Klotho co-receptor (green) and CD163 (red) in children without NAFLD (A), with NAFLD NASH− (B) and with NASH+ (C). (D–F) Co-staining of Klotho co-receptor (green) and cytokeratin 8/18 (red) in children without NAFLD (D), with NAFLD NASH− (E) and with NASH+ (F). (G–I) Co-staining of Klotho co-receptor (green) and alpha-SMA (red) in children without NAFLD (G), with NAFLD NASH− (H) and with NASH+ (I). Yellow arrows indicate hepatic stellate cells. The white bar represents a 30 µm length. (J) Histological scores for panels from A to I.

References

    1. Alisi A, Manco M, Vania A, Nobili V (2009) Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 155: 469–474.
    1. Brunt EM (2010) Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7: 195–203.
    1. Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C (2011) Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 17: 3082–3091.
    1. Alisi A, Cianfarani S, Manco M, Agostoni C, Nobili V (2012) Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med 44: 29–40.
    1. Alisi A, Locatelli M, Nobili V (2010) Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 13: 397–402.
    1. Kim KH, Jeong YT, Oh H, Kim SH, Cho JM, et al. (2013) Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med 19: 83–92.
    1. Angelin B, Larsson TE, Rudling M (2012) Circulating fibroblast growth factors as metabolic regulators–a critical appraisal. Cell Metab 16: 693–705.
    1. Kliewer SA, Mangelsdorf DJ (2010) Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 91: 254S–257S.
    1. Itoh N (2010) Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 342: 1–11.
    1. Kurosu H, Kuro-O M (2009) The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 299: 72–78.
    1. Jones SA (2012) Physiology of FGF15/19. Adv Exp Med Biol 728: 171–182.
    1. Kharitonenkov A (2009) FGFs and metabolism. Curr Opin Pharmacol 9: 805–810.
    1. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) FGF21 corrects obesity in mice. Endocrinology 149: 6018–6027.
    1. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58: 250–259.
    1. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594–2603.
    1. Yan H, Xia M, Chang X, Xu Q, Bian H, et al. (2011) Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS One 6: e24895.
    1. Eren F, Kurt R, Ermis F, Atug O, Imeryuz N, et al. (2012) Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin Biochem 45: 655–658.
    1. Morris-Stiff G, Feldstein AE (2010) Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. J Hepatol 53: 795–796.
    1. Lohman TG, Roche AF, Martorell R (1988) Anthropometric standardization reference manual. Champaign, IL: Human Kinetics Books, 55–70.
    1. Cacciari E, Milani S, Balsamo A, Dammacco F, De Luca F, et al. (2002) Italian cross-sectional growth charts for height, weight and BMI (6–20 y). Eur J Clin Nutr 56: 171–180.
    1. Manco M, Bedogni G, Marcellini M, Devito R, Ciampalini P, et al. (2008) Waist circumference correlates with liver fibrosis in children with non alcoholic steatohepatitis. Gut 57: 1283–1287.
    1. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313–1321.
    1. Koenker R (2005) Quantile Regression. Cambridge U. Press.
    1. Royston P, Sauerbrei W (2008) Multivariable Model-building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables. Chichester, UK: Wiley.
    1. Hilbe JM (2009) Logistic Regression Models. Boca Raton, FL: Chapman & Hall/CRC.
    1. Long JS, Freese J (2008) Regression Models for Categorical Dependent Variables Using Stata. 2nd ed. College Station, TX: Stata Press.
    1. Kurosu H, Kuro-O M (2009) The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 299: 72–78.
    1. Shu G, Xie B, Ren F, Liu DC, Zhou J, et al. (2013) Restoration of klotho expression induces apoptosis and autophagy in hepatocellular carcinoma cells. Cell Oncol (Dordr) 36: 121–129.
    1. Reinehr T, Woelfle J, Wunsch R, Roth CL (2012) Fibroblast Growth Factor 21 (FGF-21) and Its Relation to Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver in Children: A Longitudinal Analysis. J Clin Endocrinol Metab 97: 2143–2150.
    1. Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, et al. (2012) Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 54: 700–713.
    1. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH (2009) Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 51: 371–379.
    1. Chartoumpekis DV, Ziros PG, Psyrogiannis AI, Papavassiliou AG, Kyriazopoulou VE, et al. (2011) Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice. Diabetes 60: 2465–2473.
    1. Díaz-Delfín J, Hondares E, Iglesias R, Giralt M, Caelles C, et al. (2012) TNF-α Represses β-Klotho Expression and Impairs FGF21 Action in Adipose Cells: Involvement of JNK1 in the FGF21 Pathway. Endocrinology 153: 4238–4245.
    1. Barutcuoglu B, Basol G, Cakir Y, Cetinkalp S, Parildar Z, et al. (2011) Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 41: 390–396.
    1. Schreuder TC, Marsman HA, Lenicek M, van WervenJR, Nederveen AJ, et al. (2010) The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 298: G440–445.
    1. Adams AC, Coskun T, Rovira AR, Schneider MA, Raches DW, et al. (2012) Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 7: e38438.
    1. Latasa MU, Salis F, Urtasun R, Garcia-Irigoyen O, Elizalde M, et al. (2012) Regulation of Amphiregulin Gene Expression by β-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System. PLoS One 7: e52711.
    1. Adams AC, Cheng CC, Coskun T, Kharitonenkov A (2012) FGF21 Requires βklotho to Act In Vivo. PLoS One 7: e49977.
    1. Yang C, Jin C, Li X, Wang F, McKeehan WL, et al. (2012) Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 7: e33870.
    1. Chen L, Liu H, Liu J, Zhu Y, Xu L, et al. (2013) Klotho Endows Hepatoma Cells with Resistance to Anoikis via VEGFR2/PAK1 Activation in Hepatocellular Carcinoma. PLoS One 8: e58413.
    1. Huang CL (2012) Regulation of ion channels by secreted Klotho. Adv Exp Med Biol 728: 100–106.

Source: PubMed

3
订阅